Search | Médecins Sans Frontières Access Campaign

About us
About the Access Campaign

Some of our 2023 plans

Media room

Latest news

Jobs
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Our work
COVID-19

Explainer: A bold proposal at the WTO by India and South Africa

Diabetes

Drug-resistant infections

HIV/AIDS

Hepatitis C

Hypertension

Patents and intellectual property

Pandemic prevention, preparedness and response

The Patent Oppositions Database

Research and development

Spotlight on: the Big Pharma double-dip

Transparency Matters: Clinical Trials Costs

Tropical and neglected diseases

Spotlight on: Snakebite

Tuberculosis

Vaccines

Explainer: COVID-19 vaccines - Recommendations for equitable access
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Get involved
Campaign success stories

#NoMoreTears Johnson & Johnson Can you hear us?

A Fair Shot

Novartis 'Drop the case'

Trans-pacific Partnership (TPP)

Recent campaigns

Time for $5

No Patents in a Pandemic

Share the Tech - Save Lives
Take Action

Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Resources
Press releases

Statements

Letters

Opinion articles

Feature stories

Interviews

Blog

Newsletters

Publications

Research articles

Topic overview pages

Spotlight pages

Videos

Photo stories

Infographics

Events
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action

6 results found
There are 5 active filters
Clear all filters
lopinavir/ritonavir
Press release

6 results found

Thumbnail

Press release |

29 November 2018

Pharmaceutical corporations failing children with HIV

MSF criticises pharma for dragging feet on developing HIV drugs for children.

Tags HIV/AIDS HIV/AIDS lopinavir/ritonavirdolutegravir CiplaMerckViiV

Gloria Chipasula, 11 years old MSF's HIV and TB positive patient stands in in the middle of the road (green dressed) as she plays with her young relatives and village's friends.

Press release |

06 June 2017

Press note: Child-friendly formulation of WHO-recommended HIV treatment now approved by the CDSCO

Tags HIV/AIDS antiretroviral medicineslopinavir/ritonavir Delhi Network of Positive PeopleDNDi India

A woman holds a sign at the Stop Stock Outs (SSP) activist meeting in Soshanguve, a township outside of Pretoria on April 16, 2015.

Press release |

27 October 2015

South Africa Should Override Patent on Key HIV Medicine After Widespread Stock Out Problem

Tags HIV/AIDSIntellectual property and trade HIV/AIDS antiretroviral medicineslopinavir/ritonavir compulsory licencestock out AbbVie Fix the Patent Laws Campaign South Africa

Press release |

10 November 2011

Brazilians demand greater access to crucial HIV drug

Tags HIV/AIDSIntellectual property and trade antiretroviral medicineslopinavir/ritonavir compulsory licencepatent opposition Abbott Brazil

Press release |

07 January 2011

India Rejects Patents for Two Key AIDS Drugs

Tags HIV/AIDSIntellectual property and trade atazanavirlopinavir/ritonavir World Health OrganizationAbbottBristol-Myers Squibb India

Press release |

15 March 2006

Access denied to crucial new HIV/AIDS medicines

Tags HIV/AIDS HIV/AIDS antiretroviral medicineslopinavir/ritonavir Abbott